New chemo drug may be more effective in certain patient groups
A phase three clinical trial of eribulin mesylate suggested it may be the optimal treatment in certain patient populations.
Results from a phase three clinical trial indicate that a potential new chemotherapy drug called eribulin mesylate could be more effective than the commonly-administered capecitabine in certain types of cancer patients.
As medical advancements are made, treatment of the disease is becoming increasingly personalised in order to ensure the most favourable outcomes, and the new medicine could help doctors better tailor their curative or palliative strategies.
Findings presented by Dr Peter A Kaufman during the 2013 ASCO Annual Meeting, which was held in Chicago, indicate that eribulin mesylate is superior to the alternative in patients with three or more organs involved with metastatic breast cancer.
Those who have not undergone chemotherapy, which involves the administration of cytotoxic drugs to eradicate populations of diseased cells, for six months also stand to benefit, as do patients who have received anthracycline and/or a taxane therapies in the metastatic setting.
Dr Kaufman, of the Dartmouth-Hitchcock Geisel School of Medicine and Norris Cotton Cancer Center, said: "These exploratory analyses suggest that other patient subgroups may benefit from eribulin and further studies are warranted."
Related News
-
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News A Day in the Life of a President and Chief Scientific Officer
We are continuing to get to know the people working day-to-day behind the pharma companies shaping the industry, the ones who keep the wheels turning and ultimately bring better healthcare to the population; we are talking to the individuals at the hea... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News LEAP-ing into the future of pharma – the CPHI Middle East Vision
On March 6, 2024, the CPHI team hosted the Future of Pharma Forum at LEAP 2024, Saudi Arabia’s premier destination for tech leaders and innovators to meet and collaborate. -
News Informa Markets International Women’s Day Panel Discussion
On March 7, 2024, the Informa Markets Amsterdam office hosted an International Women’s Day Breakfast and Panel Discussion to celebrate the women who drive the B2B events industry forward, including members of the CPHI team. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance